Critical Analysis: Clene (NASDAQ:CLNN) versus Isodiol International (OTCMKTS:ISOLF)

Isodiol International (OTCMKTS:ISOLF) and Clene (NASDAQ:CLNN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Profitability

This table compares Isodiol International and Clene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Isodiol International	N/A	N/A	N/A
Clene	-25,009.70%	N/A	-137.98%

Insider and Institutional Ownership

23.3% of Clene shares are held by institutional investors. 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Isodiol International and Clene, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Isodiol International	0	0	0	0	0.00
Clene	1	0	6	0	2.71

Clene has a consensus target price of $33.25, indicating a potential upside of 529.73%. Given Clene’s stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than Isodiol International.

Valuation & Earnings

This table compares Isodiol International and Clene”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Isodiol International	N/A	N/A	N/A	N/A	N/A
Clene	$134,000.00	503.49	-$26.17 million	($3.20)	-1.65

Isodiol International has higher earnings, but lower revenue than Clene.

Summary

Clene beats Isodiol International on 6 of the 8 factors compared between the two stocks.

About Isodiol International

Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions in Canada and the United States. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; provision of apparel and merchandising solutions; manufactures and sells hemp infused beverages; and supplies pharmaceutical products. The company is headquartered in Vancouver, Canada.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.